Literature DB >> 17010108

Reduced myocarditis following Coxsackievirus infection in cellular FLICE inhibitory protein--long form-transgenic mice.

Sally Huber1, Austin Dohrman, Danielle Sartini, Ralph C Budd.   

Abstract

Cellular FLICE inhibitory protein--long form (c-FLIP(L)) is a caspase-defective homologue of caspase-8 that blocks apoptosis by death receptors. c-FLIP(L) expression in T cells can also augment activation of the mitogen-activated protein kinase, extracellular signal-related kinase, as well as nuclear factor-kappaB. This contributes to increased production of interleukin-2 and CD25, resulting in hyperproliferation of T cells from c-FLIP(L)-transgenic mice. c-FLIP also heterodimerizes with and activates caspase-8, resulting in increased death of T cells and a selection of a T helper 2 cytokine profile. The effects of c-FLIP on cytolytic function of CD8(+) T cells have not been examined previously. We studied the cytolytic capacity of T cells from c-FLIP(L)-transgenic mice using an antigen-specific system, as well as the consequences during a viral immune response to Coxsackievirus B3 (CVB3). The increased T-cell receptor (TCR) signalling due to c-FLIP did not alter the cytolytic machinery but did reduce cytotoxicity because of decreased surface expression of TCR and CD8. It also produced a Tc2 cytokine profile. These effects of c-FLIP collectively served to diminish the severity of CVB3-induced myocarditis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010108      PMCID: PMC2265828          DOI: 10.1111/j.1365-2567.2006.02469.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  On the dynamics of TCR:CD3 complex cell surface expression and downmodulation.

Authors:  H Liu; M Rhodes; D L Wiest; D A Vignali
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

2.  The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways.

Authors:  T Kataoka; R C Budd; N Holler; M Thome; F Martinon; M Irmler; K Burns; M Hahne; N Kennedy; M Kovacsovics; J Tschopp
Journal:  Curr Biol       Date:  2000-06-01       Impact factor: 10.834

3.  c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis.

Authors:  David W Chang; Zheng Xing; Yi Pan; Alicia Algeciras-Schimnich; Bryan C Barnhart; Shoshanit Yaish-Ohad; Marcus E Peter; Xiaolu Yang
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

4.  Structural basis for the activation of human procaspase-7.

Authors:  S J Riedl; P Fuentes-Prior; M Renatus; N Kairies; S Krapp; R Huber; G S Salvesen; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  Liver damage by infiltrating CD8+ T cells is Fas dependent.

Authors:  N J Kennedy; J Q Russell; N Michail; R C Budd
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

6.  NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development.

Authors:  R E Voll; E Jimi; R J Phillips; D F Barber; M Rincon; A C Hayday; R A Flavell; S Ghosh
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

7.  Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3.

Authors:  Wenfang Wu; Ravi S Misra; Jennifer Q Russell; Richard A Flavell; Mercedes Rincón; Ralph C Budd
Journal:  J Biol Chem       Date:  2006-02-02       Impact factor: 5.157

8.  The caspase 8 inhibitor c-FLIP(L) modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes.

Authors:  Susanne M A Lens; Takao Kataoka; Karen A Fortner; Antoine Tinel; Isabel Ferrero; Robson H MacDonald; Michel Hahne; Friedrich Beermann; Antoine Attinger; Hans-Acha Orbea; Ralph C Budd; Jürg Tschopp
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.

Authors:  Hyung J Chun; Lixin Zheng; Manzoor Ahmad; Jin Wang; Christina K Speirs; Richard M Siegel; Janet K Dale; Jennifer Puck; Joie Davis; Craig G Hall; Suzanne Skoda-Smith; T Prescott Atkinson; Stephen E Straus; Michael J Lenardo
Journal:  Nature       Date:  2002-09-26       Impact factor: 49.962

10.  Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses.

Authors:  M Rescigno; V Piguet; B Valzasina; S Lens; R Zubler; L French; V Kindler; J Tschopp; P Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  5 in total

Review 1.  The role of sex differences in autophagy in the heart during coxsackievirus B3-induced myocarditis.

Authors:  Andreas Koenig; Adam Sateriale; Ralph C Budd; Sally A Huber; Iwona A Buskiewicz
Journal:  J Cardiovasc Transl Res       Date:  2013-12-10       Impact factor: 4.132

2.  Caspase-8 and FLIP regulate RIG-I/MDA5-induced innate immune host responses to picornaviruses.

Authors:  Iwona A Buskiewicz; Andreas Koenig; Sally A Huber; Ralph C Budd
Journal:  Future Virol       Date:  2012-12       Impact factor: 1.831

Review 3.  FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP.

Authors:  Yuichi Tsuchiya; Osamu Nakabayashi; Hiroyasu Nakano
Journal:  Int J Mol Sci       Date:  2015-12-18       Impact factor: 5.923

Review 4.  Interaction between the Hepatitis B Virus and Cellular FLIP Variants in Viral Replication and the Innate Immune System.

Authors:  Ah Ram Lee; Yong Kwang Park; Mehrangiz Dezhbord; Kyun-Hwan Kim
Journal:  Viruses       Date:  2022-02-11       Impact factor: 5.048

5.  c-FLIP-Short reduces type I interferon production and increases viremia with coxsackievirus B3.

Authors:  Iwona A Buskiewicz; Andreas Koenig; Brian Roberts; Jennifer Russell; Cuixia Shi; Sun-Hwa Lee; Jae U Jung; Sally A Huber; Ralph C Budd
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.